Cargando…
Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?
BACKGROUND: The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (ICU). MAI...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675378/ https://www.ncbi.nlm.nih.gov/pubmed/33213445 http://dx.doi.org/10.1186/s12910-020-00562-7 |
_version_ | 1783611658905583616 |
---|---|
author | Marinelli, Enrico Busardò, Francesco Paolo Zaami, Simona |
author_facet | Marinelli, Enrico Busardò, Francesco Paolo Zaami, Simona |
author_sort | Marinelli, Enrico |
collection | PubMed |
description | BACKGROUND: The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (ICU). MAIN TEXT: Having to make such decisions certainly entails substantial difficulties, and that has led many health care professional to seek ethical guidance. The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has attempted to meet that growing need by a set of recommendations, applying “clinical soundness” as a beacon standard; that approach tends to prioritize patients with higher life expectancy, which could be characterized as a “moderately utilitarian” approach. Yet, such a selection has engendered daunting ethical quandaries. The authors believe it can only be warranted and acceptable if rooted in a transparent decision-making process and verifiable, reviewed criteria. Moreover, the authors have stressed how clinical experimentation in a pandemic setting is a subtext of great interest from an ethical perspective. In Italy, no drug therapy and trials were undertaken for COVID-19 patients for a rather long period of time. When the epidemic was already circulating, an intervention proved necessary on the system of administrative procedures, aimed at expediting the authorization and validation of protocols, then bogged down by bureaucracy. A new system has since been instituted by a government decree that was signed about one month after the first Covid-19 case was officially recorded in the country. Such a swift implementation, which took just a few weeks, is noteworthy and proves that clinical trials can be initiated in a timely fashion, even with a pandemic unfolding. The concerted, action of supportive care and RCTs is the only way to attain effective forms of treatments for COVID-19 and any other future outbreak. CONCLUSIONS: The authors have arrived at the conclusion that the most effective and ethically sound response on the part of any national health care system would be to adequately reconfigure its organizational mechanisms, by making clinical trials and all related administrative procedures consistent with the current state of emergency. |
format | Online Article Text |
id | pubmed-7675378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76753782020-11-19 Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency? Marinelli, Enrico Busardò, Francesco Paolo Zaami, Simona BMC Med Ethics Debate BACKGROUND: The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (ICU). MAIN TEXT: Having to make such decisions certainly entails substantial difficulties, and that has led many health care professional to seek ethical guidance. The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has attempted to meet that growing need by a set of recommendations, applying “clinical soundness” as a beacon standard; that approach tends to prioritize patients with higher life expectancy, which could be characterized as a “moderately utilitarian” approach. Yet, such a selection has engendered daunting ethical quandaries. The authors believe it can only be warranted and acceptable if rooted in a transparent decision-making process and verifiable, reviewed criteria. Moreover, the authors have stressed how clinical experimentation in a pandemic setting is a subtext of great interest from an ethical perspective. In Italy, no drug therapy and trials were undertaken for COVID-19 patients for a rather long period of time. When the epidemic was already circulating, an intervention proved necessary on the system of administrative procedures, aimed at expediting the authorization and validation of protocols, then bogged down by bureaucracy. A new system has since been instituted by a government decree that was signed about one month after the first Covid-19 case was officially recorded in the country. Such a swift implementation, which took just a few weeks, is noteworthy and proves that clinical trials can be initiated in a timely fashion, even with a pandemic unfolding. The concerted, action of supportive care and RCTs is the only way to attain effective forms of treatments for COVID-19 and any other future outbreak. CONCLUSIONS: The authors have arrived at the conclusion that the most effective and ethically sound response on the part of any national health care system would be to adequately reconfigure its organizational mechanisms, by making clinical trials and all related administrative procedures consistent with the current state of emergency. BioMed Central 2020-11-19 /pmc/articles/PMC7675378/ /pubmed/33213445 http://dx.doi.org/10.1186/s12910-020-00562-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Debate Marinelli, Enrico Busardò, Francesco Paolo Zaami, Simona Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency? |
title | Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency? |
title_full | Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency? |
title_fullStr | Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency? |
title_full_unstemmed | Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency? |
title_short | Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency? |
title_sort | intensive and pharmacological care in times of covid-19: a “special ethics” for emergency? |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675378/ https://www.ncbi.nlm.nih.gov/pubmed/33213445 http://dx.doi.org/10.1186/s12910-020-00562-7 |
work_keys_str_mv | AT marinellienrico intensiveandpharmacologicalcareintimesofcovid19aspecialethicsforemergency AT busardofrancescopaolo intensiveandpharmacologicalcareintimesofcovid19aspecialethicsforemergency AT zaamisimona intensiveandpharmacologicalcareintimesofcovid19aspecialethicsforemergency |